Sorbonne Université, INSERM, UMR_S 938, Centre de Recherche Saint-Antoine-Team Proliferation and Differentiation of Stem Cells, Assistance Publique-Hôpitaux de Paris, Hôpital Pitié Salpêtrière, Service d'Hématologie, Paris, France.
Haematology, Queen's University Belfast Faculty of Medicine Health and Life Sciences, Belfast, United Kingdom.
Biol Blood Marrow Transplant. 2020 Sep;26(9):1559-1566. doi: 10.1016/j.bbmt.2020.04.016. Epub 2020 May 15.
Melphalan at a myeloablative dose followed by autologous stem cell transplantation (ASCT) remains the standard of care for transplant-eligible patients with myeloma. However, therapies such as new immunomodulatory drugs and proteasome inhibitors and, more recently, monoclonal antibodies and chimeric antigen receptor T cells are challenging the traditional role of ASCT. Which patients benefit from ASCT? Can its use be delayed until first relapse? The field is moving rapidly as novel agents lead to new patient care strategies. The place of ASCT in this changing landscape will be reviewed and reassessed.
马法兰大剂量化疗联合自体造血干细胞移植（ASCT）仍然是适合移植的骨髓瘤患者的标准治疗方法。然而，新的免疫调节剂和蛋白酶体抑制剂等治疗方法，以及最近的单克隆抗体和嵌合抗原受体 T 细胞，正在挑战 ASCT 的传统作用。哪些患者受益于 ASCT？它的使用能否推迟到首次复发时？随着新型药物的出现带来新的患者治疗策略，该领域正在迅速发展。ASCT 在这一不断变化的格局中的地位将得到回顾和重新评估。
